Cellular mechanisms of interleukin-12-mediated neuroblastoma regression
- PMID: 12596103
- DOI: 10.1053/jpsu.2003.50043
Cellular mechanisms of interleukin-12-mediated neuroblastoma regression
Abstract
Background/purpose: Interleukin-12 (IL-12) is a proinflammatory cytokine with potent antitumor effects. Previous studies from the authors laboratory showed regression of established neuroblastoma in mice vaccinated with IL-12 transduced dendritic cells (DC). Although regression was associated with intense T cell infiltration, the precise role of T cells is unknown. The purpose of this work is to study the cellular mechanisms in IL-12-mediated tumor regression.
Methods: Three groups of mice (n = 12) received subcutaneous inoculation with 1 x 10(6) murine neuroblastoma cells (TBJ). Anti-CD4 (T helper), anti-CD8 (T cytotoxic), or antiasialo-GM1 (natural killer) antibodies were injected intravenously at 3-day intervals to deplete various immune effector cell populations. Mice in each depletion group and the control (nondepleted) group were injected intratumorally on day 7 with 1 x 10(6) DC IL-12-transduced DC. Tumors were harvested for morphometry and immunohistochemistry at 21 days.
Results: CD4 depletion had no effect on tumor growth in either control or IL-12-vaccinated animals. In contrast, CD8-depleted animals treated with IL-12-transduced DC underwent initial regression followed by progressive tumor growth (P <.01). These tumors were smaller in size at the same time-point. However, NK cell depletion (antiasialo GM1) completely abrogated the antitumor effects of IL-12-transduced DC, leading to progressive tumor growth from the outset. There was no difference between the control and treated animals in this group.
Conclusions: Contrary to our hypothesis that IL-12 DC primarily function to stimulate a T cell-mediated response, these data suggest that NK cells are essential for the initial antitumor response of animals treated with IL-12-transduced DC. CD8+ T cells appear to be necessary effector cells for complete rejection of tumor and possibly memory. NK cells are responsible for the early immune response. Furthermore, CD4+ (T helper) cells did not play any role in IL-12-induced regression. These results imply that for DC to generate an effective antitumor response against neuroblastoma both acquired and innate effector cells are required.
Copyright 2003, Elsevier Science (USA). All rights reserved.
Similar articles
-
Interleukin-12 transduced dendritic cells induce regression of established murine neuroblastoma.J Pediatr Surg. 2001 Aug;36(8):1285-92. doi: 10.1053/jpsu.2001.25796. J Pediatr Surg. 2001. PMID: 11479878
-
Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo.J Pediatr Surg. 2003 Mar;38(3):301-7; discussion 301-7. doi: 10.1053/jpsu.2003.50098. J Pediatr Surg. 2003. PMID: 12632339
-
CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes.Eur J Immunol. 1995 Jan;25(1):137-46. doi: 10.1002/eji.1830250124. Eur J Immunol. 1995. PMID: 7843224
-
T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance.Crit Rev Immunol. 2001;21(1-3):215-48. Crit Rev Immunol. 2001. PMID: 11642606 Review.
-
Combination therapy with interleukin-2 and antitumor monoclonal antibodies.Cancer J Sci Am. 1997 Dec;3 Suppl 1:S121-7. Cancer J Sci Am. 1997. PMID: 9457407 Review.
Cited by
-
Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of neuroblastoma.PLoS One. 2013 Oct 10;8(10):e77753. doi: 10.1371/journal.pone.0077753. eCollection 2013. PLoS One. 2013. PMID: 24130898 Free PMC article.
-
Immune therapies for neuroblastoma.Cancer Biol Ther. 2009 May;8(10):874-82. doi: 10.4161/cbt.8.10.8358. Epub 2009 May 9. Cancer Biol Ther. 2009. PMID: 19342881 Free PMC article. Review.
-
Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow.J Immunol. 2009 Apr 1;182(7):4328-38. doi: 10.4049/jimmunol.0800471. J Immunol. 2009. PMID: 19299733 Free PMC article.
-
IL-12 immunotherapy of murine leukaemia: comparison of systemic versus gene modified cell therapy.J Cell Mol Med. 2009 Aug;13(8B):1962-1976. doi: 10.1111/j.1582-4934.2008.00412.x. J Cell Mol Med. 2009. PMID: 18624776 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials